Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Thumbnail
View/Open
Date
2019
Author
Sezer, A.
Ozyilkan, O.
Metadata
Show full item record
URI
https://www.jto.org/article/S1556-0864(19)31849-0/pdf
http://hdl.handle.net/11727/4936
Collections